A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects

NCT01923207 ↗

Phase 1 Completed 32 enrolled Shire Dyax Corp. · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of the study drug (DX-2930) administered subcutaneously in healthy subjects. Subjects will be randomized to receive DX-2930 or placebo.

Timeline

Start: 2013-08-12
Primary completion: 2014-01-07
Completion: 2014-01-07

Publications

Results Chyung Y, Vince B, Iarrobino R, Sexton D, Kenniston J, Faucette R, TenHoor C, Stolz LE, Stevens C, Biedenkapp J, Adelman B. A phase 1 study investigating DX-2930 in healthy subjects. Ann Allergy Asthma Immunol. 2014 Oct;113(4):460-6.e2. doi: 10.1016/j.anai.2014.05.028. Epub 2014 Jun 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lanadelumab	Monoclonal antibody	0.1 mg/kg	Subcutaneous
Subject	Lanadelumab	Monoclonal antibody	0.3 mg/kg	Subcutaneous
Subject	Lanadelumab	Monoclonal antibody	1 mg/kg	Subcutaneous
Subject	Lanadelumab	Monoclonal antibody	3 mg/kg	Subcutaneous

A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects

Summary

Timeline

Publications

Drugs

Indications